Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 18/20 | 0.75 |
| ▸ | CA1 | P00915 | 17/20 | 0.75 |
| ▸ | CA2 | P00918 | 17/20 | 0.75 |
| ▸ | CA12 | O43570 | 8/20 | 0.72 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | CA7 | P43166 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15828111 | 0.94 | CA9 (0.83) | CA9CA1CA2CA12CA14 | |
| SCHEMBL2234764 | 0.92 | CA9 (0.83) | CA9CA1CA2CA12CA14 | |
| SCHEMBL23169164 | 0.91 | CA9 (0.78) | CA9CA1CA2CA12CA14 | |
| SCHEMBL12231697 | 0.91 | CA9 (0.75) | CA9CA1CA2CA12CA14 | |
| SCHEMBL25341857 | 0.91 | CA9 (0.66) | CA9CA1CA2CA12CA14 | |
| SCHEMBL412012 | 0.91 | CA9 (0.78) | CA9CA1CA2CA12CA14 | |
| SCHEMBL29699213 | 0.91 | CA9 (0.78) | CA9CA1CA2CA12CA14 | |
| SCHEMBL19788026 | 0.91 | CA9 (0.62) | CA9CA1CA2CA12CA14 | |
| SCHEMBL12231957 | 0.90 | CA9 (0.72) | CA9CA1CA2CA12CA14 | |
| SCHEMBL19545067 | 0.90 | CA9 (0.67) | CA9CA1CA2CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133705-A1 | TREHALOSE ANALOGUES | CENTRAL MICHIGAN UNIVERSITY | 2023-05-04 | — | — | US | disclosed |
| US-11535642-B2 | Trehalose analogues | CENTRAL MICHIGAN UNIVERSITY (US) | 2022-12-27 | — | — | US | disclosed |
| US-10995110-B2 | Trehalose analogues | CENTRAL MICHIGAN UNIVERSITY (US) | 2021-05-04 | — | — | US | disclosed |
| US-10869939-B2 | Delivery system in micellar form having modular spectral response based on enzyme-responsive amphiphilic PEG-dendron hybrid polymers | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2020-12-22 | — | — | US | disclosed |
| US-10836720-B2 | Inhibitors of integrin alpha 5 beta 1 and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-11-17 | — | — | US | disclosed |
| US-10759821-B2 | Trehalose analogues | CENTRAL MICHIGAN UNIVERSITY (US) | 2020-09-01 | — | — | US | disclosed |
| US-20200115408-A1 | TREHALOSE ANALOGUES | CENTRAL MICHIGAN UNIVERSITY | 2020-04-16 | — | — | US | disclosed |
| US-20190144386-A1 | INHIBITORS OF INTEGRIN ALPHA 5 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-05-16 | — | — | US | disclosed |
| US-9874562-B2 | Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses | ACADEMIA SINICA (TW) | 2018-01-23 | — | — | US | disclosed |
| WO-2017173302-A2 | INHIBITORS OF INTEGRIN ALPHA 5 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-10-05 | — | — | WO | disclosed |
| US-9119885-B2 | RGD-containing peptidomimetics and uses thereof | STEBA BIOTECH S.A. (LU) | 2015-09-01 | — | — | US | disclosed |
| US-20140154181-A1 | RGD-CONTAINING PEPTIDOMIMETICS AND USES THEREOF | STEBA BIOTECH S.A. (LU) | 2014-06-05 | — | — | US | disclosed |
| US-8318504-B2 | MRP2 efflux pathway prognostic method | NORGINE BV (NL) | 2012-11-27 | — | — | US | disclosed |
| US-20120263649-A1 | DETECTION OF MYCOBACTERIA | ISIS INNOVATION LIMITED (GB) | 2012-10-18 | — | — | US | disclosed |
| US-20100272675-A1 | METHOD OF ADMINISTERING CONJUGATES | ENDOCYTE, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| WO-2010097604-A2 | NEW COMPOUNDS | UCL BUSINESS PLC (GB) | 2010-09-02 | — | — | WO | disclosed |
| US-7544454-B2 | Photoreceptor layer having rhodamine additive | XEROX CORPORATION (US) | 2009-06-09 | — | — | US | disclosed |
| WO-2009027679-A1 | PROCESS FOR THE PREPARATION OF GUANIDINO SUBSTITUTED BI-AND POLYPHENYLS THAT ARE SUITABLE AS SMALL MOLECULE CARRIERS | UCL BUSINESS PLC (GB) | 2009-03-05 | — | — | WO | disclosed |
| US-20080311498-A1 | PHOTORECEPTOR LAYER HAVING RHODAMINE ADDITIVE | XEROX CORPORATION (US) | 2008-12-18 | — | — | US | disclosed |
| US-7427462-B2 | Photoreceptor layer having rhodamine additive | XEROX CORPORATION (US) | 2008-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133705-A1 | TREHALOSE ANALOGUES | TREH, TALDO1, GALE | CA9 1512/4885CA1 2754/4885CA2 3388/4885 |
| US-20200115408-A1 | TREHALOSE ANALOGUES | TREH, TALDO1, GALE | CA9 1512/4885CA1 2754/4885CA2 3388/4885 |
| US-20140154181-A1 | RGD-CONTAINING PEPTIDOMIMETICS AND USES THEREOF | GRPR, VIP, PROKR1 | CA9 968/4885CA1 597/4885CA2 1512/4885 |
| US-10995110-B2 | Trehalose analogues | TREH, TALDO1, GALE | CA9 1512/4885CA1 2754/4885CA2 3388/4885 |
| US-20190144386-A1 | INHIBITORS OF INTEGRIN ALPHA 5 BETA 1 AND METHODS OF USE | ITGA5, ITGB5, ITGB1 | CA9 1517/4885CA1 1284/4885CA2 2330/4885 |
| US-20120263649-A1 | DETECTION OF MYCOBACTERIA | LY96, MICA, CD74 | CA9 2871/4885CA1 2576/4885CA2 1447/4885 |
| US-10759821-B2 | Trehalose analogues | TREH, TALDO1, GALE | CA9 1512/4885CA1 2754/4885CA2 3388/4885 |
| US-20100272675-A1 | METHOD OF ADMINISTERING CONJUGATES | CD47, C3AR1, C5AR1 | CA9 2751/4885CA1 1413/4885CA2 3834/4885 |
| US-10836720-B2 | Inhibitors of integrin alpha 5 beta 1 and methods of use | ITGA5, ITGB5, ITGB1 | CA9 1517/4885CA1 1284/4885CA2 2330/4885 |
| US-11535642-B2 | Trehalose analogues | TREH, TALDO1, GALE | CA9 1512/4885CA1 2754/4885CA2 3388/4885 |
| US-10869939-B2 | Delivery system in micellar form having modular spectral response based on enzyme-responsive amphiphilic PEG-dendron hybrid polymers | JMJD7, HM13, APEH | CA9 591/4885CA1 473/4885CA2 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.